Interesting. I found some really insightful articles from 2016/2017 about Moderna’s venture into the same sphere. I’ll link a few, but here’s a quote.
“In order to protect mRNA molecules from the body’s natural defenses, drug developers must wrap them in a protective casing. For Moderna, that meant putting its Crigler-Najjar therapy in nanoparticles made of lipids. And for its chemists, those nanoparticles created a daunting challenge: Dose too little, and you don’t get enough enzyme to affect the disease; dose too much, and the drug is too toxic for patients.”
Interesting. I found some really insightful articles from 2016/2017 about Moderna’s venture into the same sphere. I’ll link a few, but here’s a quote.
“In order to protect mRNA molecules from the body’s natural defenses, drug developers must wrap them in a protective casing. For Moderna, that meant putting its Crigler-Najjar therapy in nanoparticles made of lipids. And for its chemists, those nanoparticles created a daunting challenge: Dose too little, and you don’t get enough enzyme to affect the disease; dose too much, and the drug is too toxic for patients.”
That’s from this article
https://www.statnews.com/2017/01/10/moderna-trouble-mrna/#
But read this one first because it gives many insights into the company and came out the year prior.
https://www.statnews.com/2016/09/13/moderna-therapeutics-biotech-mrna/